

SECRETARY OF THE
06 AUG 22 AM 10:

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
-----------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name Novartis Vaccines and Diagnostics, Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported 1300 I (Eye) Street NW, Suite 1090 E Washington DC 20005 USA			
3. Principal place of business (if different than line 2) City: _____ State/Zip or Country: _____			
4a. Contact Name Ms. Marguerite D. Baxter		b. Telephone number 202-962-8640	c. E-mail marguerite_baxter@chiron.com.
7. Client Name <input checked="" type="checkbox"/> Self Novartis Vaccines and Diagnostics, Inc.			5. Senate ID # 2901155-12
			6. House ID # 36887000

TYPE OF REPORT 8. Year 2006 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>1,141,000</u></p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

000231355

Marguerite D. Baxter

Signature Marguerite Baxter

Senate Password

Date 8/14/2006

Printed Name and Title Marguerite D. Baxter, V.P. Government Affairs



Registrant Name Novartis Vaccines and Diagnostics, Inc.

Client Name Novartis Vaccines and Diagnostics, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

S.2564 A bill to prepare and strengthen the biodefenses of the United States against deliberate, accidental, and natural outbreaks of illness, and for other purposes. Lobbied in support of vaccine manufacturing interests and for an antitrust provision to effectively address influenza pandemic.

17. House(s) of Congress and Federal agencies contacted None House Senate Other

Department of Health and Human Services
Centers for Disease Control and Prevention

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	Net
Marguerite D. Baxter		<input type="checkbox"/>
David Keaney		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000231356

Signature Marguerite Baxter

Date 8/14/2006

Printed Name and Title Marguerite D. Baxter, V.P. Government Affairs

Registrant Name Novartis Vaccines and Diagnostics, Inc.

Client Name Novartis Vaccines and Diagnostics, Inc.

ADDENDUM for General Lobbying Issue Area HCR

16. Specific lobbying issues (continued from previous page)

S.3678 Pandemic and All Hazards Preparedness Act. A bill to amend the Public Health Service Act with respect to public health security and all-hazards preparedness and response, and for other purposes. Lobbied for a vaccine distribution tracking system that is similar to the current CDC voluntary system.

H.R.5533 Biodefense and Pandemic Vaccine and Drug Development Act of 2006. To prepare and strengthen the biodefenses of the United States against deliberate, accidental, and natural outbreaks of illness, and for other purposes. Lobbied to support vaccine manufacturing interests and for an antitrust provision to address influenza pandemic.

HR 5122, National Defense Authorization Act for Fiscal Year 2007, pandemic influenza.

S.2766, Department of Defense Authorization Act for Fiscal year 2007, pandemic influenza

S. 1873, Biodefense and Pandemic Vaccine and Drug Development Act of 2006, pandemic influenza antitrust provisions

0000231357

Registrant Name Novartis Vaccines and Diagnostics, Inc.

Client Name Novartis Vaccines and Diagnostics, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD - Budget/Appropriations (one per page)

16. Specific lobbying issues

H.R.4939 Emergency Supplemental Appropriations for FY 2006, Section 2607 and Title IV, pandemic influenza funding and pandemic vaccine liability.
HR 5384, FY 2007 Agriculture, Rural Development, Food and Drug Administration Appropriation Bill - House version, pandemic preparedness and to ensure that the FDA Funding is sufficient to support pandemic preparedness and a rapid regulatory pathway to approve new influenza technology.

17. House(s) of Congress and Federal agencies contacted None House Senate Other

Department of Health and Human Services
Centers for Disease Control and Prevention

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	Net
Marguerite Baxter		<input type="checkbox"/>
David Keaney		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000231358

Printed Name and Title Marguerite D. Baxter, V.P. Government Affairs

Registrant Name Novartis Vaccines and Diagnostics, Inc.

Client Name Novartis Vaccines and Diagnostics, Inc.

ADDENDUM for General Lobbying Issue Area BUD

16. Specific lobbying issues (continued from previous page)

H.R. 5631 FY 2007 Department of Defense Appropriations bill, House version of the bill, pandemic influenza related provisions.

H.R.5441, FY 2007 Homeland Security Appropriations Bill, House version, Title III, Countermeasure and pandemic provisions

H.R.5647, FY 2007 Labor, Health and Human Services, and Education and Related Agencies Appropriations bill, Title II, Centers for Disease Control and Prevention funding and pandemic influenza

HR 5385, FY 2007 Military Quality of Life, Military Construction, Department of VA and related agencies Appropriation bill, avian influenza issues

000231359

Registrant Name Novartis Vaccines and Diagnostics, Inc.

Client Name Novartis Vaccines and Diagnostics, Inc.

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

City

State/Zip

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues that **no longer** pertain

HOM

CPT

TAX

MMM

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal place of Business (city and state or country)

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
Novartis Corporation	Lichstrasse 35 WSJ Basel SWI	BASEL Swi	\$0	100

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrant, client or affiliated organization

Signature

Marguerite D. Baxter

Date

8/14/2006

Printed Name and Title

Marguerite D. Baxter, V.P. Government Affairs

0000231360

